The results of our study indicate that DB ± IL-2 is more effective than NAXI+GM-CSF in the treatment of patients with relapsed or refractory neuroblastoma in the bone or bone marrow who have demonstrated a partial response, a minor response or stable disease following previous therapy. The gene discussed is IL2; the disease is neuroblastoma.